Send to

Choose Destination
Kobe J Med Sci. 2016 Jul 5;62(2):E27-37.

Effects of VLA-1 Blockade on Experimental Inflammation in Mice.

Author information

Department of Integrated Drug Discovery Sciences, Kobe University Graduate School of Medicine, Kobe, Japan.
Pharmacology Research Laboratories I, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Department of Hospital Pharmacy, Kobe University School of Medicine, Kobe, Japan.


VLA-1 (very late antigen-1) is implicated in recruitment, retention and activation of leukocytes and its blockade has been referred as a potential target of new drug discovery to address unmet medical needs in inflammatory disease area. In the present study, we investigate the effects of an anti-murine CD49a (integrin α subunit of VLA-1) monoclonal antibody (Ha31/8) on various experimental models of inflammatory diseases in mice. Pretreatment with Ha31/8 at an intraperitoneal dose of 250 µg significantly (P<0.01) reduced arthritic symptoms and joint tissue damage in mice with type II collagen-induced arthritis. In addition, Ha31/8 at an intraperitoneal dose of 100 µg significantly (P<0.01) inhibited airway inflammatory cell infiltration induced by repeated exposure to cigarette smoke. In contrast, Ha31/8 failed to inhibit oxazolone-induced chronic dermatitis and OVA-induced airway hyperresponsiveness at an intraperitoneal dose of 100 µg. These results show that VLA-1 is involved, at least partly, in the pathogenesis of type II collagen-induced arthritis and cigarette smoke-induced airway inflammatory cell infiltration in mice, indicating the therapeutic potential of VLA-1 blockade against rheumatoid arthritis and chronic occlusive pulmonary disease.


Airway inflammation; Arthritis; Dermatitis; Ha31/8; Inflammation; VLA-1

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Kobe University School of Medicine Icon for PubMed Central
Loading ...
Support Center